NewAmsterdam Pharma Co N.V. is advancing obicetrapib, a next-generation oral CETP inhibitor targeting LDL cholesterol reduction in patients inadequately served by current statins. Clinical data from multiple Phase 3 trials demonstrate meaningful LDL-C lowering and favorable safety, underpinning ongoing cardiovascular outcome studies and exploration into other indications. Despite no product revenue and sustained net losses, the company maintains a strong liquidity position to fund development and US commercial infrastructure buildout. The partnership with Menarini for European commercialization complements its US strategy but regulatory and healthcare policy risks remain significant headwinds. Investors will closely monitor PREVAIL CVOT readouts and regulatory filings for commercial viability milestones.